Asymchem Laboratories (Tianjin) Co., Ltd. (SHE:002821)
China · Delayed Price · Currency is CNY 114.41
-3.00 (-2.56%)
Apr 17, 2026, 3:04 PM CST
SHE:002821 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 6,664 | 5,797 | 7,819 | 10,230 | 4,632 |
Other Revenue | 6.4 | 7.56 | 6.28 | - | - |
| 6,670 | 5,805 | 7,825 | 10,230 | 4,632 | |
Revenue Growth (YoY) | 14.91% | -25.82% | -23.51% | 120.85% | 47.67% |
Cost of Revenue | 3,928 | 3,393 | 3,833 | 5,398 | 2,582 |
Gross Profit | 2,743 | 2,412 | 3,993 | 4,833 | 2,050 |
Selling, General & Admin | 975.22 | 1,069 | 984.9 | 987.88 | 594.33 |
Research & Development | 593.26 | 614.49 | 707.86 | 708.89 | 387.48 |
Other Operating Expenses | 35.64 | 104.56 | 74.45 | - | 22.38 |
Operating Expenses | 1,675 | 1,793 | 1,773 | 1,723 | 1,004 |
Operating Income | 1,068 | 618.69 | 2,220 | 3,110 | 1,046 |
Interest Expense | -12.75 | -9.51 | -5.91 | -10.53 | -7.33 |
Interest & Investment Income | 292.02 | 292.96 | 297.73 | 76.63 | 12.99 |
Earnings From Equity Investments | - | - | - | 33.05 | -3.84 |
Currency Exchange Gain (Loss) | -123.8 | 130.43 | -5.41 | 433.61 | 1.29 |
Other Non Operating Income (Expenses) | -2.95 | -6.83 | -4.64 | -24.73 | 94.34 |
EBT Excluding Unusual Items | 1,221 | 1,026 | 2,501 | 3,618 | 1,143 |
Gain (Loss) on Sale of Investments | 21.96 | 39.57 | 17.31 | 106.9 | 49.97 |
Gain (Loss) on Sale of Assets | -2.51 | 0.16 | -0.01 | - | - |
Asset Writedown | -9.04 | -23.97 | -19.27 | - | - |
Other Unusual Items | 55.36 | 30.85 | 57.65 | - | - |
Pretax Income | 1,286 | 1,072 | 2,557 | 3,725 | 1,193 |
Income Tax Expense | 159.74 | 136.63 | 306.31 | 430.31 | 123.69 |
Earnings From Continuing Operations | 1,127 | 935.76 | 2,251 | 3,295 | 1,069 |
Minority Interest in Earnings | 5.93 | 13.19 | 17.99 | 7 | 0.02 |
Net Income | 1,133 | 948.95 | 2,269 | 3,302 | 1,069 |
Preferred Dividends & Other Adjustments | - | - | - | 2.31 | 1.01 |
Net Income to Common | 1,133 | 948.95 | 2,269 | 3,299 | 1,068 |
Net Income Growth | 19.35% | -58.17% | -31.28% | 208.77% | 48.56% |
Shares Outstanding (Basic) | 358 | 353 | 362 | 366 | 340 |
Shares Outstanding (Diluted) | 358 | 353 | 362 | 367 | 341 |
Shares Change (YoY) | 1.60% | -2.67% | -1.16% | 7.43% | 4.12% |
EPS (Basic) | 3.16 | 2.69 | 6.26 | 9.02 | 3.15 |
EPS (Diluted) | 3.16 | 2.69 | 6.26 | 9.00 | 3.13 |
EPS Growth | 17.47% | -57.03% | -30.47% | 187.43% | 42.68% |
Free Cash Flow | 137.22 | 124.33 | 2,308 | 1,136 | -1,547 |
Free Cash Flow Per Share | 0.38 | 0.35 | 6.37 | 3.10 | -4.53 |
Dividend Per Share | 1.300 | 1.100 | 1.800 | 1.800 | 0.571 |
Dividend Growth | 18.18% | -38.89% | - | 215.02% | 33.32% |
Gross Margin | 41.12% | 41.55% | 51.02% | 47.24% | 44.25% |
Operating Margin | 16.01% | 10.66% | 28.37% | 30.40% | 22.57% |
Profit Margin | 16.98% | 16.35% | 28.99% | 32.25% | 23.06% |
Free Cash Flow Margin | 2.06% | 2.14% | 29.50% | 11.11% | -33.39% |
EBITDA | 1,557 | 1,075 | 2,648 | 3,433 | 1,243 |
EBITDA Margin | 23.34% | 18.53% | 33.83% | 33.56% | 26.83% |
D&A For EBITDA | 488.89 | 456.69 | 427.82 | 323.16 | 197.16 |
EBIT | 1,068 | 618.69 | 2,220 | 3,110 | 1,046 |
EBIT Margin | 16.01% | 10.66% | 28.37% | 30.40% | 22.57% |
Effective Tax Rate | 12.42% | 12.74% | 11.98% | 11.55% | 10.37% |
Revenue as Reported | 6,670 | 5,805 | 7,825 | - | - |
Advertising Expenses | 18.67 | 31.68 | 12.46 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.